These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 37294961)

  • 1. Mantle cell lymphoma-Update on molecular biology, prognostication and treatment approaches.
    Silkenstedt E; Dreyling M
    Hematol Oncol; 2023 Jun; 41 Suppl 1():36-42. PubMed ID: 37294961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mantle cell lymphoma-Advances in molecular biology, prognostication and treatment approaches.
    Silkenstedt E; Dreyling M
    Hematol Oncol; 2021 Jun; 39 Suppl 1():31-38. PubMed ID: 34105823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mantle cell lymphoma - advances in molecular biology, prognostication and treatment approaches.
    Silkenstedt E; Linton K; Dreyling M
    Br J Haematol; 2021 Oct; 195(2):162-173. PubMed ID: 33783838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management.
    Vose JM
    Am J Hematol; 2012 Jun; 87(6):604-9. PubMed ID: 22615102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological and clinical determinants shaping heterogeneity in mantle cell lymphoma.
    López C; Silkenstedt E; Dreyling M; Beà S
    Blood Adv; 2024 Jul; 8(14):3652-3664. PubMed ID: 38748869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on the molecular pathogenesis and clinical treatment of Mantle Cell Lymphoma (MCL): minutes of the 9th European MCL Network conference.
    Dreyling M; Hoster E; Bea S; Hartmann E; Horn H; Hutter G; Salaverria I; Pott C; Trneny M; Le Gouill S; Cortelazzo S; Szymczyk M; Jurczak W; Shpilberg O; Ribrag V; Hermine O;
    Leuk Lymphoma; 2010 Sep; 51(9):1612-22. PubMed ID: 20629519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on the molecular pathogenesis and targeted approaches of mantle cell lymphoma: summary of the 12th annual conference of the European Mantle Cell Lymphoma Network.
    Dreyling M; Amador V; Callanan M; Jerkeman M; Le Gouill S; Pott C; Rule S; Zaja F;
    Leuk Lymphoma; 2015 Apr; 56(4):866-76. PubMed ID: 25015778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mantle cell lymphoma: 2013 Update on diagnosis, risk-stratification, and clinical management.
    Vose JM
    Am J Hematol; 2013 Dec; 88(12):1082-8. PubMed ID: 24273091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive?
    Dreyling M; Ferrero S;
    Haematologica; 2016 Feb; 101(2):104-14. PubMed ID: 26830211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management.
    Vose JM
    Am J Hematol; 2015 Aug; 90(8):739-45. PubMed ID: 26103436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-Risk Mantle Cell Lymphoma in the Era of Novel Agents.
    Nabrinsky E; Danilov AV; Koller PB
    Curr Hematol Malig Rep; 2021 Feb; 16(1):8-18. PubMed ID: 33507515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances and issues in mantle cell lymphoma research: report of the 2014 Mantle Cell Lymphoma Consortium Workshop.
    Kahl BS; Gordon LI; Dreyling M; Gascoyne RD; Sotomayor EM
    Leuk Lymphoma; 2015; 56(9):2505-11. PubMed ID: 25944379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Should there be a standard therapy for mantle cell lymphoma?
    Smith MR
    Future Oncol; 2011 Feb; 7(2):227-37. PubMed ID: 21345142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Personalized approaches for treatment-naïve mantle cell lymphoma.
    Qualls D; Kumar A
    Expert Rev Hematol; 2023 Feb; 16(2):95-107. PubMed ID: 36748785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances and future directions in mantle cell lymphoma research: report of the 2016 mantle cell lymphoma consortium workshop.
    Kahl BS; Dreyling M; Gordon LI; Quintanilla-Martinez L; Sotomayor EM
    Leuk Lymphoma; 2017 Jul; 58(7):1561-1569. PubMed ID: 28140709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management.
    Vose JM
    Am J Hematol; 2017 Aug; 92(8):806-813. PubMed ID: 28699667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of Relapsed/Refractory MCL.
    Silkenstedt E; Dreyling M
    Blood; 2024 Jul; ():. PubMed ID: 39059015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents.
    Inamdar AA; Goy A; Ayoub NM; Attia C; Oton L; Taruvai V; Costales M; Lin YT; Pecora A; Suh KS
    Oncotarget; 2016 Jul; 7(30):48692-48731. PubMed ID: 27119356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toward a Risk-Tailored Therapeutic Policy in Mantle Cell Lymphoma.
    Condoluci A; Rossi D; Zucca E; Cavalli F
    Curr Oncol Rep; 2018 Aug; 20(10):79. PubMed ID: 30132080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Mantle cell lymphoma: Towards a personalized therapeutic strategy?].
    Navarro Matilla B; García-Marco JA
    Med Clin (Barc); 2015 Jun; 144(12):553-9. PubMed ID: 25023849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.